Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-10
2006-10-10
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S323000, C514S330000, C514S375000, C514S414000, C514S417000, C514S616000
Reexamination Certificate
active
07119105
ABSTRACT:
The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (τ-protein); and (iv) methods for treating neurodegenerative diseases. For instance, in one embodiment, the present invention provides a method for modulating the processing of an amyloid precursor protein (APP), the method comprising contacting a composition containing the APP with an aspartyl protease inhibitor having the formula:wherein:R1,R2and R3are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and R5and R6are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R5and R6and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within the fused ring system.
REFERENCES:
patent: 5492812 (1996-02-01), Vooheis
patent: 5872101 (1999-02-01), Munoz et al.
patent: WO 98/33795 (1998-08-01), None
Christos Ntais et al, Am J Epidemiol 2004, 159:527-536.
Kim, W. et al, Expert Opinion on Therapeutic Patents (Ashley Publications), 2002, vol. 12, No. 3, pp. 419-432.
Jaana Tyynelä et al, The EMBO Journal (2000) 19, 2786-2792.
Agarwal et al.,J. Med. Chem., 29:2519-2524 (1986).
Augelli-Szafran et al.,Ann. Reports Med. Chem., 34:21-30 (1999).
Austen et al.,Biomed. Pept. Proteins Nucleic Acids, 1:243-246 (1995).
Bahr et al.,Experimental Neurology, 129:81-94 (1994).
Baldwin et al.,Proc. Natl. Acad. Sci. USA, 90:6796-6800 (1993).
Bednarski et al.,J. Neurochem., 67(5):1845-1855 (1996).
Bednarski et al.,J. Neurosci., 17(11):4006-4021 (1997).
Bednarski et al.,NeuroReport, 9:2089-2094 (1998).
Bi et al.,Exp. Neurol., 158:312-327 (1999).
Bi et al.,J. Comp. Neuro., 401:382-394 (1998).
Braak et al.,Acta Neuropathol., 46:79-83 (1979).
Cataldo et al.,Journal of Neuropathology and Experimental Neurology, 55(6):704-715 (1996).
Cataldo et al.,Proc. Natl. Acad. Sci. USA, 87:3861-3865 (1990).
Cataldo et al.,Medical Sciences, 88:10998-11002 (1991).
Cataldo et al.,Brain Research, 513:181-192 (1990).
Chevallier et al.,Brain Res., 750:11-19 (1997).
Crawford et al.,Neurosci. Lett., 289(1):61-65 (2000), Medline Abstract 10899409.
Dreyer et al.,Eur. J. Biochem., 224:265-271 (1994).
Estus et al.,Ann. N.Y. Acad. Sci., 674:138-148 (1992).
Goode et al.,J. Cell Biol., 124:769-782 (1994).
Haque et al.,J. Med. Chem., 42:1428-1440 (1999).
Hawley et al., “The Condensed Chemical Dictionary,” 1977, Van Nostrand, New York, p. 822.
Hoffman et al.,Neuroscience Letters, 250:75-78 (1998).
II et al.,Virchows Archiv A Pathol Anat, 423:185-194 (1993).
Isahara et al.,Neuroscience, 91(1):233-249 (1999).
Jupp et al.,Biochem. J., 265:871-878 (1990).
Kenessey et al.,J. Neurochem., 69(5):2026-2038 (1997).
Kick et al.,Chemistry&Biology, 4(4):297-307 (1997).
Kick et al.,J. Med. Chem., 38:1427-1430 (1995).
Kosik et al.,Proc. Natl. Acad. Sci. USA, 83:4044-4088 (1986).
Kowall et al.,Proc. Natl. Acad. Sci. USA, 88:7247-7251 (1991).
Krafft et al.,Methods Enzymol., 241:70-86 (1994).
Kreutzberg,Arzneim.-Forsch./Drug Res.45(I), Nr. 3a, 357-360 (1995).
Lamb et al.,Nature Genet., 5:22-29 (1993).
Lee et al.,J. Am. Chem. Soc., 120:9735-9747 (1998).
Lee et al.,Science, 251:675-678 (1991).
Levy-Strumpf et al.,Oncogene, 17:3331-3340 (1998).
Lindwall et al.,J. Biol. Chem., 259(19):12241-12245 (1984).
MacKay et al.,Eur. J. Biochem., 244:414-425 (1997).
Mann et al.,Neuropathol. Appl. Neurobiol., 13:123-139 (1987).
Mateo et al.,Am. J. Med. Genet., 114(1):31-33 (2002), Medline Abstract PMID 11840502.
Matsui et al.,Ann. Neurol., 49(4):544-545 (2001), Medline Abstract PMID 11310638.
Matsuo et al.,Neuron, 13:989-1002 (1994).
Menzer et al.,Am. J. Med. Genet., 105(2):179-182 (2001), Medline Abstract PMID 11304834.
Mullan et al.,Nature Genet., 1:345-347 (1992).
Murphy et al.,J. Biol. Chem., 274(17):11914-11923 (1999).
Nakamura et al.,Neurosci. Lett., 97:215-220 (1989).
Nakanishi et al.,Exp. Neurol., 126:119-128 (1994).
Nakanishi et al.,J. Neurochem., 68:739749 (1997).
Nieto et al.,J. Neurosci.,37(1):163-170 (1990).
Ohsawa et al.,Arch. Histol. Cytol., 61(5):395-403 (1998).
Olson et al., “Annual Reports Med. Chem.,” 35:31-40 (2000).
Pearson et al.,Proc. Natl. Acad. Sci. USA, 90:10578-10582 (1993).
Purpura et al.,Brain Res., 116:1-21 (1976).
Roberg et al.,Am. J. Pathol., 152(5):1151-1156 (1988).
Selkoe,TINS, 16(10):403-409 (1993).
Wagner et al.,J. Clinical Invest., 104:1329-1332 (1999).
Weingarten et al.,Proc. Natl. Acad. Sci. USA, 72(5):1858-1862 (1975).
Wiley et al.,Med. Res. Rev., 13(3):327-384 (1993).
Williams, Jr. et al.,Biochemistry, 18:2499-2503 (1979).
Wischik et al.,Proc. Natl. Acad. Sci. USA, 85:4506-4510 (1988).
Yong et al.,Exp. Neurol., 157:150-160 (1999).
“Webster's New World Dictionary, College Ed.,” no author listed, World Publishing, p. 946 (1962).
“Developments in the Treatment of Parkinson's Disease,”Drug and Ther. Bull., 35:36-40 (1997).
Bi Xiaoning
Ellman Jonathan A.
Haque Tasir
Kuntz Irwin D.
Lee Christina E.
McKenzie Thomas C.
The Regents of the University of California
Townsend & Townsend & Crew LLP
LandOfFree
Methods for treating neurodegenerative disorders using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating neurodegenerative disorders using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating neurodegenerative disorders using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3649934